Aberdeen Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aberdeen Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-280	Closed	-$294K	–	169
2024 Q3	$294K	Sell	280 -10	-3%	-$11.1K	0.19%	122
2024 Q2	$305K	Sell	290 -10	-3%	-$9.69K	0.21%	117
2024 Q1	$289K	Hold	300	–	–	0.17%	125
2023 Q4	$263K	Hold	300	–	–	0.19%	125
2023 Q3	$247K	Hold	300	–	–	0.19%	125
2023 Q2	$216K	Hold	300	–	–	0.16%	137
2023 Q1	$247K	Sell	300 -50	-14%	-$37.7K	0.18%	129
2022 Q4	$253K	Hold	350	–	–	0.19%	131
2022 Q3	$241K	Hold	350	–	–	0.21%	121
2022 Q2	$207K	Hold	350	–	–	0.16%	138
2022 Q1	$244K	Hold	350	–	–	0.17%	135
2021 Q4	$221K	Sell	350 -25	-7%	-$15.4K	0.14%	137
2021 Q3	$227K	Hold	375	–	–	0.22%	115
2021 Q2	$209K	Buy	+375	New	+$190K	0.19%	124
2020 Q3	–	Sell	-361	Closed	-$225K	–	144
2020 Q2	$225K	Sell	361 -84	-19%	-$47.7K	0.24%	112
2020 Q1	$217K	Buy	+445	New	+$184K	0.26%	105

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aberdeen Wealth Management's REGN Position: Q4 2024 in Review

Aberdeen Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 280 shares — an estimated $294K sold.

Aberdeen Wealth Management first reported a position in REGN in Q1 2020 and held it in 16 quarters. The position peaked at $305K in Q2 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Aberdeen Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Aberdeen Wealth Management sold 280 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $294K.
Aberdeen Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 16 quarters.
Aberdeen Wealth Management's Regeneron Pharmaceuticals position peaked at $305K in Q2 2024.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Aberdeen Wealth Management's 13F filing for Q4 2024, filed 21 Feb 2025.